TREATMENT AND PREVENTION OF NEURONAL CELL LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE
Disclosed herein are methods of treating and preventing neuronal cell loss in a subject using ornithine in combination with phenylacetate or phenylbutyrate. In some embodiments, the subject has received or will receive a surgical procedure (for example, liver transplantation) for treating a liver disease. In some embodiments, the subject suffers from a liver disease and hypotension.
1 . A method of treating a condition of neuron loss, comprising administering ornithine in combination with at least one of phenylacetate and phenylbutvrate to a subject in need thereof, and thereby relieving the condition, wherein the subject is a patient that had a liver disease and has experienced a traumatic bleeding.
2 . A method of preventing a condition of neuron loss, comprising administering ornithine in combination with at least one of phenylacetate and phenylbutvrate to a subject in need thereof, and thereby preventing the condition, wherein the subject is a patient having a liver disease that is expected to experience a traumatic bleeding, a patient having a liver disease that is going to be treated by liver transplantation, or a patient suffering from hypotension.
3 . The method of claim 1 , wherein the liver disease is a chronic liver disease.
4 . The method of claim 1 , wherein the liver disease is hepatic encephalopathy, cirrhosis or minimal hepatic encephalopathy.
5 . (canceled)
6 . (canceled)
7 . The method of claim 1 , wherein the traumatic bleeding is caused by a surgical procedure for treating the liver disease or by traumatic injury.
8 . (canceled)
9 . (canceled)
10 . The method of claim 1 , at least one symptom of the condition of neuron loss is one or more of decreased count of neurons in the subject, decreased count of neurons in the frontal cortex of the subject, decreased count of functional neurons in the subject, and decreased count of functional neurons in the frontal cortex of the subject.
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . The method of claim 1 , wherein the condition of neuron loss is caused by hypotension.
15 . The method of claim 1 , wherein the treatment of the condition is achieved by reducing the level of one or more cellular stress proteins in the subject, or reducing apoptotic cell death in the subject.
16 . The method of claim 2 , wherein the prevention of the condition is achieved by reducing the level of one or more cellular stress proteins in the subject.
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . A method of treating a condition of neuron loss, comprising administering ornithine in combination with at least one of phenylacetate and phenylbutyrate to a subject in need thereof, and thereby relieving the condition, wherein the subject is a patient having a liver disease that has been treated by liver transplantation or a patient suffering from hypotension.
21 . (canceled)
22 . The method of claim 20 , wherein the liver disease is a chronic liver disease.
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . The method of claim 20 , wherein the hypotension is caused by blood loss.
27 . The method of claim 2 , wherein the subject is suffering from a liver disease.
28 . (canceled)
29 . (canceled)
30 . The method of claim 20 , at least one symptom of the condition of neuron loss is one or more of decreased count of neurons in the subject, decreased count of neurons in the frontal cortex of the subject, decreased count of functional neurons in the subject, and decreased count of functional neurons in the frontal cortex of the subject.
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . The method of claim 20 , wherein the treatment of the condition is achieved by reducing the level of one or more cellular stress proteins in the subject, or by reducing apoptotic cell death in the subject.
36 . (canceled)
37 . (canceled)
38 . The method of claim 1 , wherein separate pharmaceutically acceptable salts of the ornithine and at least one of phenylacetate and phenylbutvrate are administered to the subject.
39 . The method of claim 1 , wherein the at least one of phenylacetate and phenylbutyrate is administered as a sodium phenylacetate or sodium phenylbutyrate.
40 . The method of claim 1 , wherein the ornithine is administered as a free monomelic amino acid or physiologically acceptable salt thereof.
41 . The method of claim 1 , wherein the ornithine and phenylacetate is administered as ornithine phenylacetate.
42 . The method of claim 1 , wherein the administration is oral, intravenous, intraperitoneal, intragastric, or intravascular administration.
43 . (canceled)
44 . (canceled)